11C-Acetate PET/CT Monitoring Therapy of Multiple Myeloma

Zhu, Wenjia; Dang, Yongyan; Ma, Yanru; Li, Fang; Huo, Li

doi:10.1097/rlu.0000000000001215

Cited by 4 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been some reports comparing AC-PET and FDG-PET in the clinical examination of MM. In two single-case reports, AC-PET appeared to be more sensitive than FDG-PET in assessing the tumor burden and/or response to therapy 16 , 17 . In addition, there only two cohort studies have been published to date, which compared these two imaging methods for this disease.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma

Chen

Zhu

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

The optimal method of tumor burden evaluation in newly diagnosed multiple myeloma (NDMM) is yet to be determined. This study aimed to compare the value of 11C-acetate positron-emission tomography (PET)/computed tomography (CT) (AC-PET and 18F-fluorodeoxyglucose PET/CT (FDG-PET) in the assessment of tumor burden in NDMM. This study evaluated 64 NDMM patients between February 2015 and July 2018. AC-PET and FDG-PET were used to assess myeloma lesions. The clinical data, imaging results, and their correlations were analyzed. Diffuse bone marrow uptake in AC-PET was significantly correlated with biomarkers for tumor burden, including serum hemoglobin (P = 0.020), M protein (P = 0.054), the percentage of bone marrow plasma cells (P < 0.001), and the Durie–Salmon stage of the disease (P = 0.007). The maximum standard uptake value (SUVmax) of focal lesions and high diffuse bone marrow uptake in AC-PET showed stronger correlations with high-risk disease (P = 0.017, P = 0.013) than those in FDG-PET. Moreover, the presence of diffuse bone marrow uptake, more than ten focal lesions, and an SUVmax of focal lesions of > 6.0 in AC-PET, but not in FDG-PET, predicted a higher probability of disease progression and shorter progression-free survival (P < 0.05). AC-PET outperformed FDG-PET in tumor burden evaluation and disease progression prediction in NDMM.

show abstract

Section: Discussionmentioning

confidence: 96%

“…Some researchers have concluded that AC-PET outperformed FDG-PET in the diagnosis, risk stratification, and treatment monitoring of MM. However, the existing studies were limited due to the small number of participants 16 – 18 , and the correlation between AC-PET imaging analysis and MM prognosis is unclear 19 .…”

Section: Introductionmentioning

confidence: 99%

11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma

Chen

Zhu

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…We propose that ACSS2 represents a novel therapeutic target for treating any tumor that has high ACSS2 expression and readily consumes acetate as an alternative nutrient source. Fortunately, 11 C-acetate PET is an established imaging tool in the clinic that has been extensively used for cancer detection (57)(58)(59)(60)(61)(62) and has also been used to study acetate-dependent fatty acid synthesis in preclinical models (15,52). 11 C-acetate PET imaging could easily be applied to help identify patients with cancer whose tumors are "hot" for acetate uptake.…”

Section: Discussionmentioning

confidence: 99%

Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth

et al. 2021

View full text Add to dashboard Cite

Acetyl-CoA is a vitally important and versatile metabolite used for many cellular processes including fatty acid synthesis, ATP production, and protein acetylation. Recent studies have shown that cancer cells upregulate acetyl-CoA synthetase 2 (ACSS2), an enzyme that converts acetate to acetyl-CoA, in response to stresses such as low nutrient availability and hypoxia. Stressed cancer cells use ACSS2 as a means to exploit acetate as an alternative nutrient source. Genetic depletion of ACSS2 in tumors inhibits the growth of a wide variety of cancers. However, there are no studies on the use of an ACSS2 inhibitor to block tumor growth. In this study, we synthesized a small-molecule inhibitor that acts as a transition-state mimetic to block ACSS2 activity in vitro and in vivo. Pharmacologic inhibition of ACSS2 as a single agent impaired breast tumor growth. Collectively, our findings suggest that targeting ACSS2 may be an effective therapeutic approach for the treatment of patients with breast cancer. Significance: These findings suggest that targeting acetate metabolism through ACSS2 inhibitors has the potential to safely and effectively treat a wide range of patients with cancer.

show abstract

Therapy assessment in multiple myeloma with PET

Nanni¹,

Zamagni²

2017

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Multiple myeloma is a plasma cell dyscrasia producing bone lytic lesions. In recent years, a wide spectrum of therapeutic approaches are available to treat the disease: an accurate therapy assessment has, therefore, become of utmost importance. In this field, imaging is becoming a cornerstone, especially in association with clinical parameters. Among imaging procedures, FDG PET/CT is recognized to provide reliable information, achieved in a very safe and fast procedure. The literature has produced very concordant results from different groups assessing the value of FDG PET/CT as a prognostic factor in general and in therapy assessment, but some issues remain regarding a standardization of image interpretation especially in borderline cases. So far, no data regarding nor other imaging compounds and the use of hybrid tomographs PET/MR are available to define therapy assessment in PET.

show abstract

11C-Acetate PET/CT Monitoring Therapy of Multiple Myeloma

Cited by 4 publications

References 24 publications

11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma

11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma

Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth

Therapy assessment in multiple myeloma with PET

Contact Info

Product

Resources

About